Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
Falagario UG, Beksac AT, Martini A, Cumarasamy S, Gupta A, Prasad S, Thulasidass H, Shah QN, Jayaratna I, Lewis S, Rastinehad AR, Taouli B, Cormio L, Carrieri G, Tewari AK.
Falagario UG, et al. Among authors: prasad s.
J Urol. 2019 Jul;202(1):102-107. doi: 10.1097/JU.0000000000000134. Epub 2019 Jun 7.
J Urol. 2019.
PMID: 30730408